TROPHAMINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).

How it works

TROPHAMINE is a balanced amino acid injection that provides essential and non-essential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It serves as a substrate for gluconeogenesis and stimulates insulin secretion.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and decarboxylation pathways; primarily in the liver and kidney.
Excretion	Primarily renal (80-90%) as unchanged drug; minor biliary/fecal excretion (5-10%).
Half-life	Terminal elimination half-life is 1.5-2 hours in adults; prolonged in renal impairment.
Protein binding	Approximately 30% bound to albumin.
Volume of Distribution	0.2-0.4 L/kg; small Vd indicating limited tissue distribution.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate (seconds to minutes).
Duration of Action	Duration is 4-6 hours; dose-dependent; shorter with higher doses due to rapid clearance.

Classification & Brands

Dosing & administration

Intravenous infusion: 500-1000 mL per day (providing 6-10 g of amino acids) administered at a rate not exceeding 250 mL per hour. Dosage based on protein and calorie requirements.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 25 mL/min) due to risk of azotemia. For moderate impairment (GFR 25-50 mL/min), reduce dose by 50% and monitor BUN and creatinine.
Liver impairment	Contraindicated in severe hepatic failure (Child-Pugh class C). For Child-Pugh class B, reduce dose by 50% and monitor ammonia levels. Use with caution in class A.
Pediatric use	Neonates and infants: 2-3 g of amino acids per kg per day. For older children: 1-2 g/kg/day. Administer as continuous infusion over 24 hours. Adjust based on nitrogen balance and growth parameters.
Geriatric use	No specific dose adjustment; administer at lower end of dosing range (500 mL per day) due to potential decreased renal function. Monitor fluid and electrolyte balance closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).

Breastfeeding

It is not known whether TROPHAMINE is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when TROPHAMINE is administered to a nursing woman. No M/P ratio is available.

Teratogenic Risk

TROPHAMINE is a sterile, hypertonic amino acid solution used for parenteral nutrition. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Because animal reproduction studies are not always predictive of human response, TROPHAMINE should be used during pregnancy only if clearly needed. Potential fetal risks include electrolyte imbalances, acid-base disturbances, and metabolic complications secondary to maternal use.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe metabolic acidosis","Hepatic coma or severe hepatic impairment","Hyperammonemia","Inborn errors of amino acid metabolism (e.g., phenylketonuria)"]

Clinical Precautions

Precautions

["Monitor serum electrolytes, blood urea nitrogen (BUN), creatinine, and acid-base balance frequently.","Risk of hyperkalemia due to potassium content.","Avoid administration of amino acids in patients with metabolic acidosis, hepatic impairment, or hyperammonemia.","Use with caution in patients with diabetes mellitus due to insulin response.","Ensure proper mixing and sterile preparation to prevent infection or phlebitis."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TROPHAMINE

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).

How it works

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and decarboxylation pathways; primarily in the liver and kidney.
Excretion	Primarily renal (80-90%) as unchanged drug; minor biliary/fecal excretion (5-10%).
Half-life	Terminal elimination half-life is 1.5-2 hours in adults; prolonged in renal impairment.
Protein binding	Approximately 30% bound to albumin.
Volume of Distribution	0.2-0.4 L/kg; small Vd indicating limited tissue distribution.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate (seconds to minutes).
Duration of Action	Duration is 4-6 hours; dose-dependent; shorter with higher doses due to rapid clearance.

Classification & Brands

Dosing & administration

Intravenous infusion: 500-1000 mL per day (providing 6-10 g of amino acids) administered at a rate not exceeding 250 mL per hour. Dosage based on protein and calorie requirements.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR < 25 mL/min) due to risk of azotemia. For moderate impairment (GFR 25-50 mL/min), reduce dose by 50% and monitor BUN and creatinine.
Liver impairment	Contraindicated in severe hepatic failure (Child-Pugh class C). For Child-Pugh class B, reduce dose by 50% and monitor ammonia levels. Use with caution in class A.
Pediatric use	Neonates and infants: 2-3 g of amino acids per kg per day. For older children: 1-2 g/kg/day. Administer as continuous infusion over 24 hours. Adjust based on nitrogen balance and growth parameters.
Geriatric use	No specific dose adjustment; administer at lower end of dosing range (500 mL per day) due to potential decreased renal function. Monitor fluid and electrolyte balance closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TROPHAMINE (TROPHAMINE).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to any component","Severe metabolic acidosis","Hepatic coma or severe hepatic impairment","Hyperammonemia","Inborn errors of amino acid metabolism (e.g., phenylketonuria)"]